score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Investigate Actionability	Clinical evidence			Mutational Burden	High Mutational Burden								Investigate Actionability	Ipilimumab	CTLA-4 inhibition	Immunotherapy	In a study of malignant melanoma using a discovery cohort of 25 patients and a validation cohort of 39 patients, a significantly higher muational burden was seen in patients with a long-term clinical benefit vs. patients with minimal or no benefit to ipilimumab treatment.	Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189-99.	https://doi.org/10.1056/NEJMoa1406498													0				 mutations per Mb		MEL-IPI_Pat159		
Investigate Actionability			Inferential	Aneuploidy	Whole genome doubling																						Investigate Actionability	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						MEL-IPI_Pat159		
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Nonsense	p.Q262*	0.4098	61.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677						0				BRCA1 p.Q262* (Nonsense)	0.0	MEL-IPI_Pat159	MEL-IPI_Pat159-Tumor-SM-5VWK2	MEL-IPI_Pat159-Normal-SM-5VWIJ
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	BRCA2	Missense	p.S1597F	0.359	78.0	0.0	0.0		Investigate Actionability	Nivolumab + Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Responders were enriched for mutation in BRCA2 mutations, mostly nonsense mutations. 6 of 21 responders had BRCA2 vs. 1 of 17 nonresponders.	Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma Cell. 2016; 165(1):35-44.	https://doi.org/10.1016/j.cell.2016.02.065	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677						0				BRCA2 p.S1597F (Missense)		MEL-IPI_Pat159	MEL-IPI_Pat159-Tumor-SM-5VWK2	MEL-IPI_Pat159-Normal-SM-5VWIJ
Investigate Actionability	Clinical evidence			Copy Number	EGFR	Deletion				0.0	0.0		Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Amplification and mutation of EGFR was associated with better clinical outcomes in a trial of 66 non-small cell lung cancer patients who had experienced relapse after surgery.	Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005;23(28):6829-37.	https://doi.org/10.1200/JCO.2005.01.0793													0				EGFR Deletion	1.0	MEL-IPI_Pat159	MEL-IPI_Pat159-Tumor-SM-5VWK2	
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.P676T	0.1429	28.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0.0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744	0				ARID1A p.P676T (Missense)		MEL-IPI_Pat159	MEL-IPI_Pat159-Tumor-SM-5VWK2	MEL-IPI_Pat159-Normal-SM-5VWIJ
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.H419Y	0.4	15.0	0.0	0.0																Investigate Actionability	0.0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				PTPN11 p.H419Y (Missense)		MEL-IPI_Pat159	MEL-IPI_Pat159-Tumor-SM-5VWK2	MEL-IPI_Pat159-Normal-SM-5VWIJ
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Splice Site	p.A461T	0.5357	28.0	0.0	0.0																Investigate Actionability	0.0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				PTPN11 p.A461T (Splice Site)		MEL-IPI_Pat159	MEL-IPI_Pat159-Tumor-SM-5VWK2	MEL-IPI_Pat159-Normal-SM-5VWIJ
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.G462E	0.3704	27.0	0.0	0.0																Investigate Actionability	0.0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				PTPN11 p.G462E (Missense)		MEL-IPI_Pat159	MEL-IPI_Pat159-Tumor-SM-5VWK2	MEL-IPI_Pat159-Normal-SM-5VWIJ
Investigate Actionability			Clinical evidence	Copy Number	ESR1	Deletion				0.0	0.0																Investigate Actionability	0.0	Ampifications of ESR1 was significantly associated with poor disease-free survival and overall survival in a study of 99 patients with ER-positive breast cancer tumors.	Nielsen KV, Ejlertsen B, Muller S, et al. Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer. Breast Cancer Res Treat. 2011;127(2):345-55.	https://doi.org/10.1007/s10549-010-0984-y	0				ESR1 Deletion		MEL-IPI_Pat159	MEL-IPI_Pat159-Tumor-SM-5VWK2	
Biologically Relevant				Somatic Variant	MTOR	Missense	p.R2152C	0.4571	35.0	8e-06	0.0																					0				MTOR p.R2152C (Missense)		MEL-IPI_Pat159	MEL-IPI_Pat159-Tumor-SM-5VWK2	MEL-IPI_Pat159-Normal-SM-5VWIJ
Biologically Relevant				Somatic Variant	NTRK1	Splice Site	p.L120L	0.3333	18.0	0.0	0.0																					0				NTRK1 p.L120L (Splice Site)		MEL-IPI_Pat159	MEL-IPI_Pat159-Tumor-SM-5VWK2	MEL-IPI_Pat159-Normal-SM-5VWIJ
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.R415Q	0.3636	11.0	0.0	0.0																					0				ESRP1 p.R415Q (Missense)		MEL-IPI_Pat159	MEL-IPI_Pat159-Tumor-SM-5VWK2	MEL-IPI_Pat159-Normal-SM-5VWIJ
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.D23N	1.0	2.0	0.0	0.0																					0				CDKN2A p.D23N (Missense)		MEL-IPI_Pat159	MEL-IPI_Pat159-Tumor-SM-5VWK2	MEL-IPI_Pat159-Normal-SM-5VWIJ
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Q400*	0.406	133.0	0.0	0.0																					0				NF1 p.Q400* (Nonsense)		MEL-IPI_Pat159	MEL-IPI_Pat159-Tumor-SM-5VWK2	MEL-IPI_Pat159-Normal-SM-5VWIJ
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.L1109*	0.5	42.0	0.0	0.0																					0				NF1 p.L1109* (Nonsense)		MEL-IPI_Pat159	MEL-IPI_Pat159-Tumor-SM-5VWK2	MEL-IPI_Pat159-Normal-SM-5VWIJ
Biologically Relevant				Somatic Variant	TPX2	Nonsense	p.E211*	0.1	40.0	0.0	0.0																					0				TPX2 p.E211* (Nonsense)		MEL-IPI_Pat159	MEL-IPI_Pat159-Tumor-SM-5VWK2	MEL-IPI_Pat159-Normal-SM-5VWIJ
Biologically Relevant				Somatic Variant	PAK1	Deletion	p.D183del	0.0698	43.0	0.0	0.0																					0				PAK1 p.D183del (Deletion)		MEL-IPI_Pat159	MEL-IPI_Pat159-Tumor-SM-5VWK2	MEL-IPI_Pat159-Normal-SM-5VWIJ
Biologically Relevant				Copy Number	FLI1	Deletion				0.0	0.0																					0				FLI1 Deletion		MEL-IPI_Pat159	MEL-IPI_Pat159-Tumor-SM-5VWK2	
Biologically Relevant				Copy Number	ATM	Deletion				0.0	0.0																					0				ATM Deletion		MEL-IPI_Pat159	MEL-IPI_Pat159-Tumor-SM-5VWK2	
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.706																									0				COSMIC Signature (version 2) 7 (71%)		MEL-IPI_Pat159		
